Have you assessed how the international operations of Phibro Animal Health (PAHC Quick QuotePAHC - Free Report) performed in the quarter ended March 2026? For this maker of animal health products and nutritional supplements, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.

In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importance on grasping the extent of a company's dependence on international markets, as it sheds light on the firm's earnings stability, its skill in leveraging various economic cycles and its broad growth potential.

Presence in international markets can act as a hedge against domestic economic downturns and provide access to faster-growing economies. However, this diversification also brings complexities due to currency fluctuations, geopolitical risks and differing market dynamics.

While delving into PAHC's performance for the past quarter, we observed some fascinating trends in the revenue from its foreign segments that are commonly modeled and observed by analysts on Wall Street.

The company's total revenue for the quarter amounted to $383.5 million, showing rise of 10.3%. We will now explore the breakdown of PAHC's overseas revenue to assess the impact of its international operations.

A Closer Look at PAHC's Revenue Streams Abroad

During the quarter, Europe, Middle East and Africa contributed $44.47 million in revenue, making up 11.6% of the total revenue. When compared to the consensus estimate of $41.02 million, this meant a surprise of +8.41%. Looking back, Europe, Middle East and Africa contributed $44.78 million, or 12%, in the previous quarter, and $38.91 million, or 11.2%, in the same quarter of the previous year.

Of the total revenue, $30.69 million came from Asia Pacific during the last fiscal quarter, accounting for 8%. This represented a surprise of +12.61% as analysts had expected the region to contribute $27.25 million to the total revenue. In comparison, the region contributed $19.77 million, or 5.3%, and $28.22 million, or 8.1%, to total revenue in the previous and year-ago quarters, respectively.

Latin America and Canada accounted for 19.7% of the company's total revenue during the quarter, translating to $75.62 million. Revenues from this region represented a surprise of +4.98%, with Wall Street analysts collectively expecting $72.04 million. When compared to the preceding quarter and the same quarter in the previous year, Latin America and Canada contributed $87.6 million (23.4%) and $70.75 million (20.3%) to the total revenue, respectively.

Prospective Revenues in International Markets

The current fiscal quarter's total revenue for Phibro, as projected by Wall Street analysts, is expected to reach $385.23 million, reflecting an increase of 1.7% from the same quarter last year. The breakdown of this revenue by foreign region is as follows: Europe, Middle East and Africa is anticipated to contribute 14.3% or $55.13 million, Asia Pacific 8.5% or $32.7 million and Latin America and Canada 22.6% or $87.19 million.

For the full year, the company is projected to achieve a total revenue of $1.48 billion, which signifies a rise of 13.9% from the last year. The share of this revenue from various regions is expected to be: Europe, Middle East and Africa at 12.6% ($185.88 million), Asia Pacific at 7.4% ($109.09 million), and Latin America and Canada at 22.6% ($334.05 million).

Wrapping Up

Phibro's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

Boasting a remarkable track record that's been externally verified, the Zacks Rank, our unique stock rating system, leverages changes in earnings projections to function as a reliable gauge for predicting short-term stock price movements.

At present, Phibro holds a Zacks Rank #2 (Buy). This ranking implies that its near-term performance might beat the overall market movement. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Phibro Animal Health's Recent Stock Market Performance

The stock has witnessed a decline of 30.9% over the past month versus the Zacks S&P 500 composite's an increase of 9.1%. In the same interval, the Zacks Medical sector, to which Phibro belongs, has registered a decrease of 2.9%. Over the past three months, the company's shares saw a decrease of 23.5%, while the S&P 500 increased by 7.1%. In comparison, the sector experienced a decline of 9.8% during this timeframe.